Related references
Note: Only part of the references are listed.Short, Highly Effective, and Inexpensive Standardized Treatment of Multidrug-resistant Tuberculosis
Armand Van Deun et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2010)
Bactericidal Potencies of New Regimens Are Not Predictive of Their Sterilizing Potencies in a Murine Model of Tuberculosis
Koen Andries et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Should Moxifloxacin Be Used for the Treatment of Extensively Drug-Resistant Tuberculosis? An Answer from a Murine Model
Julien Poissy et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Sterilizing Activity of R207910 (TMC207)-containing Regimens in the Murine Model of Tuberculosis
Murad Ibrahim et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2009)
The Diarylquinoline TMC207 for Multidrug-Resistant Tuberculosis
Andreas H. Diacon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis
M. Ibrahim et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Evaluation of new antituberculosis drugs in mouse models
G. R. Davies et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration
Nacer Lounis et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
Global incidence of multidrug-resistant tuberculosis
Matteo Zignol et al.
JOURNAL OF INFECTIOUS DISEASES (2006)
Weekly moxifloxacin and rifapentine is more active than the Denver regimen in murine tuberculosis
IM Rosenthal et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2005)
A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis
K Andries et al.
SCIENCE (2005)
Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis
EL Nuermberger et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2004)
Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis
EL Nuermberger et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2004)
Statistical limitations to the Cornell model of latent tuberculosis infection for the study of relapse rates
AJ Lenaerts et al.
TUBERCULOSIS (2004)
Fluoroquinolone-containing third-line regimen against Mycobacterium tuberculosis in vivo
N Veziris et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2003)
The treatment of multidrug-resistant tuberculosis in Turkey
K Tahaoglu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers
A Lubasch et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2000)
A nonhuman primate model for preclinical testing of new tuberculosis vaccines
DN McMurray
CLINICAL INFECTIOUS DISEASES (2000)
Share Paper
